弥漫大B细胞淋巴瘤治疗的研究进展

Progress in the treatment of diffuse large B-cell lymphoma

弥漫大B细胞淋巴瘤(DLBCL)属于侵袭性B细胞淋巴瘤,目前利妥昔单抗联合环磷酰胺+蒽环类+长春碱类+糖皮质激素(R-CHOP方案)已成为治疗DLBCL的一线治疗方案,但部分患者存在复发或疾病进展情况,针对这类患者的治疗仍是目前临床研究关注的重点。目前针对复发/难治DLBCL患者的治疗主要有抗体药物偶联物、靶向药物、免疫检查点抑制剂、细胞免疫治疗及造血干细胞移植等,有望为患者的疾病预后带来显著改善。

Diffuse large B-cell lymphoma(DLBCL)belongs to invasive B-cell lymphoma.At present,rituximab combined with cyclophosphamide,anthracycline,vinblastine and glucocorticoid(R-CHOP regimen)has become the first-line treatment plan for DLBCL,but some patients still have recurrence or disease progression.Treatment for these patients is still the focus of current clinical research,including antibody drug conjugates,targeted drugs,im-mune checkpoint inhibitors,cellular immunotherapy and hematopoietic stem cell transplantation.They are expected to bring significant improvement to the prognosis of patients.